Roche has just achieved a significant milestone with its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution receiving the CE Mark. This means the device is now approved for people over 18 with type 1 and type 2 diabetes who are on flexible insulin therapy.
Matt Sause, CEO of Roche Diagnostics, highlighted the challenges faced by those managing diabetes, emphasizing the frequent decisions required daily to maintain blood glucose levels. He believes their new CGM solution, equipped with predictive algorithms, will help address these challenges and empower users to better manage their condition, leading to healthier lives.
Despite the proven benefits of CGM technology in improving glycemic control, many diabetes patients still struggle to meet their targets. They often experience hypoglycemic episodes, particularly at night, which can severely impact their quality of life and overall health. Roche aims to alleviate these concerns with its Accu-Chek SmartGuide CGM, which not only provides real-time glucose readings every five minutes but also predicts future glucose levels and identifies risks of hypoglycemia, including nocturnal episodes.
Clinical evaluations have shown the system to be highly accurate, meeting stringent performance requirements for glucose monitoring and prediction. The integration of Accu-Chek SmartGuide with Roche’s healthcare platform allows healthcare professionals to access detailed data, facilitating personalized care and potentially improving treatment outcomes.
Designed for ease of use with a 14-day wear time, the Accu-Chek SmartGuide promises to empower individuals with diabetes to make timely therapy adjustments based on predictive insights, ultimately enhancing their ability to manage their condition proactively.
In essence, Roche’s new CGM solution represents a significant step forward in diabetes management, promising a blend of accuracy, predictive capability, and user-friendly design to support better health outcomes for patients.